TAK Relative Valuation
TAK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TAK is overvalued; if below, it's undervalued.
Historical Valuation
Takeda Pharmaceutical Co Ltd (TAK) is now in the Fair zone, suggesting that its current forward PE ratio of 27.43 is considered Fairly compared with the five-year average of 28.27. The fair price of Takeda Pharmaceutical Co Ltd (TAK) is between 9.59 to 20.42 according to relative valuation methord.
Relative Value
Fair Zone
9.59-20.42
Current Price：14.90
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.00
P/B
Median3y
0.93
Median5y
1.01
12.65
FCF Yield
Median3y
11.89
Median5y
12.94
Competitors Valuation Multiple
The average P/S ratio for TAK's competitors is 5.32, providing a benchmark for relative valuation. Takeda Pharmaceutical Co Ltd Corp (TAK) exhibits a P/S ratio of 1.48, which is -72.23% above the industry average. Given its robust revenue growth of 0.24%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Takeda Pharmaceutical Co Ltd (TAK) currently overvalued or undervalued?
What is Takeda Pharmaceutical Co Ltd (TAK) fair value?
How does TAK's valuation metrics compare to the industry average?
What is the current P/B ratio for Takeda Pharmaceutical Co Ltd (TAK) as of Jun 20 2025?
What is the current FCF Yield for Takeda Pharmaceutical Co Ltd (TAK) as of Jun 20 2025?
What is the current Forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK) as of Jun 20 2025?